世界卫生组织《2025年全球结核病报告》结核病科学研究章节解读

doi:10.19982/j.issn.1000-6621.20250507

中国防痨杂志 ›› 2026, Vol. 48 ›› Issue (3): 307-312.doi: 10.19982/j.issn.1000-6621.20250507

世界卫生组织《2025年全球结核病报告》结核病科学研究章节解读

舒薇, 刘宇红()

首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所/中国疾病预防控制中心结核病防治临床中心, 北京 101149

收稿日期:2025-12-19 出版日期:2026-03-10 发布日期:2026-03-06
通信作者: 刘宇红 E-mail:liuyuhong0516@126.com
基金资助:
国家疾病预防控制局公共卫生人才培养支持项目;北京市卫生健康委员会高层次公共卫生技术人才建设项目(学科带头人-03-11)

Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025

Shu Wei, Liu Yuhong()

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute/Clinical Center on Tuberculosis, China CDC, Beijing 101149, China

Received:2025-12-19 Online:2026-03-10 Published:2026-03-06
Contact: Liu Yuhong E-mail:liuyuhong0516@126.com
Supported by:
The National Bureau of Disease Control and Prevention Public Health Talent Training Support Project;Beijing Municipal Health Commission High Level Public Health Talent Construction Project(Discipline Leader 03-11)

摘要/Abstract

摘要：

科技创新是终结结核病流行的核心驱动力。2025年11月12日,世界卫生组织发布了《2025年全球结核病报告》。作者聚焦于报告中结核病研究领域新诊断技术、新药与新方案及新疫苗等领域的关键突破,并结合我国相关领域的研究进展进行分析,旨在为我国结核病防治工作者把握国际前沿、规划未来研究方向、开展原创性研究提供参考。

关键词: 结核, 研究, 规范, 评论

Abstract:

Technological innovation is pivotal to curbing the tuberculosis (TB) epidemic through sustained research and development. On Nov 12, 2025, World Health Organization released the Global Tuberculosis Report 2025. This paper reviews the key achievements in the areas of TB research and innovation for new diagnostics, drugs, and regimens as well as vaccines introduced in the report, and discusses some of China’s indigenous progresses in related areas. The authors aim to make China’s TB professionals better informed about the latest research development in TB prevention and control around the globe, fostering indigenous TB innovation efforts with greater originality.

Key words: Tuberculosis, Research, Benchmarking, Comment

中图分类号:

舒薇, 刘宇红. 世界卫生组织《2025年全球结核病报告》结核病科学研究章节解读[J]. 中国防痨杂志, 2026, 48(3): 307-312. doi: 10.19982/j.issn.1000-6621.20250507

Shu Wei, Liu Yuhong. Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025[J]. Chinese Journal of Antituberculosis, 2026, 48(3): 307-312. doi: 10.19982/j.issn.1000-6621.20250507

参考文献 15

[1]	屈燕, 李涛, 马文斌, 等世界卫生组织《2025年全球结核病报告》解读. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178.
[2]	World Health Organization. Moscow Declaration to End TB; First WHO global ministerial conference on ending TB in the sustainable development era: a multisectoral response. Geneva: World Health Organization and the Ministry of Health of the Russian Federation, 2017.
[3]	World Health Organization. The Global Strategy for TB research and innovation. Geneva: World Health Organization, 2020.
[4]	General Assembly of the United Nations. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2018.
[5]	General Assembly of the United Nations. litical declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2023.
[6]	Vachaspathi TD. Tuberculosis Diagnostics. New York: Treatment Action Group, 2025.
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization, 2025.
[8]	McKenna L. Tuberculosis Treatment. New York: Treatment Action Group, 2025.
[9]	Guglielmetti L, Khan U, Velásquez GE, et al. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. Lancet Respir Med, 2025, 13(9):809-820. doi:10.1016/S2213-2600(25)00194-8. URL pmid: 40683298
[10]	Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2025, 211(1):15-33. doi:10.1164/rccm.202410-2096ST.
[11]	Heinrich N, Manyama C, Koele SE, et al. Sutezolid in com-bination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. Lancet Infect Dis, 2025, 25(11):1208-1218. doi:10.1016/S1473-3099(25)00213-0. URL pmid: 40645196
[12]	Minja LT, van der Feltz I, Manyama C, et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. Lancet Infect Dis, 2025, 25(11):1219-1229. doi:10.1016/S1473-3099(25)00289-0. URL pmid: 40645198
[13]	Metcalfe JZ, Weir IR, Scarsi KK, et al. A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infect Dis, 2026, 26(1):46-54. doi:10.1016/S1473-3099(25)00436-0.
[14]	Paton NI, Cousins C, Sari IP, et al. Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial. Lancet Infect Dis, 2025, 25(10):1084-1096. doi:10.1016/S1473-3099(25)00151-3. URL pmid: 40414233
[15]	王歆尧, 姜美丽, 庞元捷, 等. 全球结核病疫苗研发进展. 中华流行病学杂志, 2025, 46(8):1473-1479. doi:10.3760/cma.j.cn112338-20241217-00806.

世界卫生组织《2025年全球结核病报告》结核病科学研究章节解读

Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王敬, 荆玮, 李维文, 朱庆东, 逄宇, 初乃惠, 聂文娟. 超疗程应用贝达喹啉对于耐多药/利福平耐药肺结核患者的疗效及安全性临床队列分析[J]. 中国防痨杂志, 2026, 48(3): 313-319.
[2]	张宇洁, 周洁, 王芸, 范琳. 血液来源的新型生物标志物对活动性肺结核的诊断价值初探[J]. 中国防痨杂志, 2026, 48(3): 320-328.
[3]	侯田勇, 任丽萍, 李静颖, 王建伟, 樊姝慧, 吴渊明, 王全红, 丁卫民. 支气管肺泡灌洗液分子生物学联合检测对涂阴肺结核患者的诊断价值[J]. 中国防痨杂志, 2026, 48(3): 329-334.
[4]	朱庆东, 赵春艳, 黄雪雯, 黄爱春, 曾春梅, 许超艳, 兰艳群, 宋畅. 宏基因组纳米孔测序在结核浆液性积液诊断及合并感染筛查中的应用价值[J]. 中国防痨杂志, 2026, 48(3): 335-341.
[5]	矫晓克, 田园, 项静灵, 聂文娟, 庞宇, 王敬. 2011—2023年HIV阴性结核性脑膜炎患者致残与死亡的影响因素分析[J]. 中国防痨杂志, 2026, 48(3): 342-348.
[6]	韦柳迎, 吴幸幸, 黄连飘, 曾春梅, 赵春艳, 宋畅, 聂文娟, 裴洁, 韦小英, 黄爱春, 朱庆东, 谢周华, 黄献珍. 复合均衡营养粉在耐多药结核病患者抗结核治疗中的应用效果分析[J]. 中国防痨杂志, 2026, 48(3): 349-355.
[7]	许良, 代婀娜, 杨永瑞, 阮文凯, 李建龙, 党荣潘, 安慧刚, 赵文韬, 李兆飞, 赵颖鑫, 李颖, 孙建民, 谭洪栋. 中医辨证论治联合标准抗结核方案对脊柱结核患者术后康复影响的研究[J]. 中国防痨杂志, 2026, 48(3): 356-365.
[8]	高岩, 彭英杰, 葛萧, 徐健, 刘晓华, 刘金龙, 王媛媛. 基于生物信息学的结核病铁死亡相关基因MT1G的筛选与鉴定[J]. 中国防痨杂志, 2026, 48(3): 366-376.
[9]	顾玉虹, 刘曾维, 伍小英, 何立乾, 张雅惠, 吴桂锋. 结核菌素皮肤试验与γ-干扰素释放试验对学校密切接触者筛查效果及影响因素分析:一项基于真实世界数据的回顾性研究[J]. 中国防痨杂志, 2026, 48(3): 377-385.
[10]	郭卉欣, 巫株华, 陈燕梅, 余美玲, 彭柯皓, 徐镠粤, 张建辉, 陈珣珣. 广东省138家结核病防治机构结核病实验室生物安全现状调查分析[J]. 中国防痨杂志, 2026, 48(3): 386-393.
[11]	曹红, 钱冰, 赵科伕, 陈丽丽, 何玉勤, 吴金菊, 陈双双, 徐瑞, 赵存喜. 2015—2024年合肥市60岁及以上老年肺结核患者流行特征分析[J]. 中国防痨杂志, 2026, 48(3): 394-404.
[12]	张健, 陈彬, 张明五, 秦家胜, 宋玉芳, 李雪静, 王伟. 浙江省长兴县农村老年人群结核分枝杆菌潜伏感染现状及变化的相关因素分析[J]. 中国防痨杂志, 2026, 48(3): 405-412.
[13]	孟秋月, 荣宁宁, 刘亚东, 杨海霞, 马明礼. 肺结核患者治疗依从性干预措施的研究进展[J]. 中国防痨杂志, 2026, 48(3): 413-418.
[14]	王娅, 张云桂. 艾滋病并发利福平耐药结核病和马尔尼菲篮状菌病一例[J]. 中国防痨杂志, 2026, 48(3): 426-428.
[15]	中国防痨协会药学专业分会. 抗结核药治疗药物监测临床应用专家共识(2025年更新版)[J]. 中国防痨杂志, 2026, 48(2): 167-187.